Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.
Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.
复制标题
DOI：
10.1155/2014/526178
复制
发表时间：
2014
影响因子：
2
通讯作者：
Pancione M
中科院分区：
文献类型：
--
作者：
Giordano G;Febbraro A;Venditti M;Campidoglio S;Olivieri N;Raieta K;Parcesepe P;Imbriani GC;Remo A;Pancione M
在过去的几十年中，我们已经逐渐观察到转移性结直肠癌（mCRC）治疗的治疗选择的改善，生存期逐渐延长。mCRC预后仍然较差，5年生存率低。靶向药物改善了标准化疗的结果。血管生成在结直肠癌的生长、增殖和转移中起着至关重要的作用，并且已经将其作为mCRC治疗的潜在靶点进行了研究。因此，作为几项III期随机试验的结果，新型抗血管生成靶向药物贝伐单抗、瑞格非尼和阿柏西普已被批准用于mCRC治疗。通过肿瘤细胞异常表达旁分泌因子形成肿瘤容许微环境，改变了肿瘤-间质相互作用，诱导促血管生成信号的扩增。最近，VAPOUR研究显示，在FOLFIRI方案中添加阿柏西普作为mCRC的二线治疗，可显著改善OS、PFS和RR。该分子代表有效的二线治疗选择，其干扰胎盘生长因子（PlGF）/血管内皮生长因子受体1（VEGFR 1）轴的独特能力使其有效靶向血管生成、炎性细胞和克服对抗血管生成一线治疗的抗性。在这里，我们讨论了阿柏西普干扰肿瘤微环境和血管生成途径的独特能力。
In the last decades, we have progressively observed an improvement in therapeutic options for metastatic colorectal cancer (mCRC) treatment with a progressive prolongation of survival. mCRC prognosis still remains poor with low percentage of 5-year survival. Targeted agents have improved results obtained with standard chemotherapy. Angiogenesis plays a crucial role in colorectal cancer growth, proliferation, and metastasization and it has been investigated as a potential target for mCRC treatment. Accordingly, novel antiangiogenic targeted agents bevacizumab, regorafenib, and aflibercept have been approved for mCRC treatment as the result of several phase III randomized trials. The development of a tumor permissive microenvironment via the aberrant expression by tumor cells of paracrine factors alters the tumor-stroma interactions inducing an expansion of proangiogenic signals. Recently, the VELOUR study showed that addition of aflibercept to FOLFIRI regimen as a second-line therapy for mCRC improved significantly OS, PFS, and RR. This molecule represents a valid second-line therapeutic option and its peculiar ability to interfere with placental growth factor (PlGF)/vascular endothelial growth factor receptor 1 (VEGFR1) axis makes it effective in targeting angiogenesis, inflammatory cells and in overcoming resistances to anti-angiogenic first-line treatment. Here, we discuss about Aflibercept peculiar ability to interfere with tumor microenvironment and angiogenic pathway.
登录
查看更多内容
影响因子：
8.8
作者：
Cassidy, J.;Clarke, S.;Diaz-Rubio, E.;Scheithauer, W.;Figer, A.;Wong, R.;Koski, S.;Rittweger, K.;Gilberg, F.;Saltz, L.
通讯作者：
Saltz, L.
影响因子：
8.4
作者：
Bokemeyer, Carsten;Van Cutsem, Eric;Koehne, Claus-Henning
通讯作者：
Koehne, Claus-Henning
影响因子：
82.9
作者：
Carmeliet, P;Moons, L;Persico, MG
通讯作者：
Persico, MG
影响因子：
6.2
作者：
De Vita, F;Orditura, M;Galizia, G
通讯作者：
Galizia, G
影响因子：
82.9
作者：
Economides, AN;Carpenter, LR;Stahl, N
通讯作者：
Stahl, N